All In Biotech

Drug Trial Radar · NCT03940404

Anlotinib Therapy in Patients With Advanced Lung Cancer.

Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.

Last checked: Nov 20, 2026Latest source record: May 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

May 2019

Primary completion

May 2020

Study completion Dec 2020

Sponsor

Lead sponsor
First People's Hospital of HangzhouAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cttq
First posted
May 7, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).

Conditions

  • Lung Neoplasms

Interventions

  • Anlotinib HydrochlorideDrug

    Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.